摘要
目的:观察两种β受体阻滞剂卡维地洛与美托洛尔对慢性充血性心力衰竭(CHF)的长期疗效。方法:慢性充血性心力衰竭患者65例,随机分为卡维地洛组32例,美托洛尔组33例,随访6个月,比较两组的心功能改善情况。结果:卡维地洛组及美托洛尔用药后两组患者左心室舒张末期内径(LVEDd)、左心室收缩期内径(LVEDs)、右心室内径(RVD)、左心房内径(LAD)显著缩小(均为P<0.01);左心室射血分数(LVEF)显著增加(卡维地洛组P<0.01,美托洛尔组P<0.05),且卡维地洛对LVEDs、RVD、LVEF的改善作用更优于美托洛尔(LVEDs、RVD均为P<0.01,LVEF为P<0.05)。结论:卡维地洛及美托洛尔均能明显改善心功能,提高生活质量,且卡维地洛疗效优于美托洛尔。
Objective:To assess the long -term effects of metoprolol and carvedilol on patients with chronic heart failure. Method:Sixty five patients with chronic congestive heart failure were randomly divided into two groups:metoprolol group, carvedilol group. The patients were followed up for 6 months. After 6 months of treatment both groups offered hemodynamic in the patients with heart failure. Result: After treating the two groups ' left ventricular end - diastolic dimension ( LVEDd ), left ventricular end - systolic dimension ( LVEDs) ,right ventricular dimension( RVD) ,left atrial dimension( LAD) were significantly decreased( P 〈 0.01 ). The left ventricular ejection fraction( LVEF) were significantly increased ,the carvedilol group( P 〈 0.01 ) , The metoprolol group ( P 〈 0.05 ). And the effect of Carvedilol is better than metoprolol (LVEDs, RVD P 〈0.01 ;LVEFP 〈0.05). Conclusion: Both carvedilol and metoprolol can improve heart funtion obvi- ously, advance the quality of life, and carvedilol is better than metoprolol
出处
《河北医学》
CAS
2007年第2期164-167,共4页
Hebei Medicine